SubsidieMeestersPharmacoepigenetics for precision medicine in type 2 diabetes
PROCEED aims to develop and commercialize blood-based epigenetic markers to predict metformin response in Type 2 diabetes patients, enhancing personalized therapy and clinical decision-making.
Projectdetails
Introduction
The prevalence of diabetes will rise to ~592 million in 2035. Type 2 diabetes (T2D) is a leading cause of death through its vascular complications. High glucose increases the risk for complications, and thereby suffering for patients and costs for society.
Importance of Optimal Therapy
It is important that patients with T2D receive an optimal therapy that lowers blood glucose. Metformin is first-line T2D therapy. However, ~30% of patients do not respond to metformin. Currently, there are no biomarkers that predict the response to metformin.
Discovery of Epigenetic Markers
We discovered blood-based epigenetic markers that could discriminate between responders and non-responders to metformin in drug-naïve patients with T2D. This epigenetic tool may be further developed to help patients with T2D receive an optimal therapy.
Project Aim
The aim of PROCEED is therefore to develop and commercialize our pharmacoepigenetic tool. We expect this biomarker tool to aid clinical decision-making in T2D therapy.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-10-2023 |
| Einddatum | 31-3-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- LUNDS UNIVERSITETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Listening to Silence: The First Blood Test for Risk of Individuals at Prophylactic Time Windows to Develop Type 2 Diabetes MellitusThis project aims to develop a clinical test using novel epigenetic biomarkers to predict Type 2 Diabetes risk in non-diabetic individuals, enabling early preventive treatments. | ERC Proof of... | € 150.000 | 2024 | Details |
GenomeDia: a personalized medicine tool for diabetesThe project aims to develop a genetic interpretation tool to subcategorize young diabetes patients, enhancing treatment by leveraging findings from whole genome sequencing. | ERC Proof of... | € 150.000 | 2024 | Details |
Circadian Control of Systemic Metabolism in Physiology and Type 2 DiabetesThis project aims to uncover how synchronizing energetic stressors with circadian rhythms can improve metabolism and inform new treatments for type 2 diabetes. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Tracking epigenetic plasticity in circulating tumor-derived DNA to monitor drug resistance and guide personalized treatment in cancer patientsEpiGuide aims to develop a blood-based assay to monitor epigenetic mechanisms of drug resistance in cancer, enhancing personalized treatment and early detection of therapy failure. | ERC Consolid... | € 1.998.625 | 2022 | Details |
Opioids and insulin secretion: a new avenue to fight type 2 diabetesThis project aims to explore the role of delta opioid receptors in insulin secretion to develop innovative drug targets for Type 2 diabetes, utilizing advanced genomic and pharmacological methods. | ERC Consolid... | € 1.997.915 | 2022 | Details |
Listening to Silence: The First Blood Test for Risk of Individuals at Prophylactic Time Windows to Develop Type 2 Diabetes Mellitus
This project aims to develop a clinical test using novel epigenetic biomarkers to predict Type 2 Diabetes risk in non-diabetic individuals, enabling early preventive treatments.
GenomeDia: a personalized medicine tool for diabetes
The project aims to develop a genetic interpretation tool to subcategorize young diabetes patients, enhancing treatment by leveraging findings from whole genome sequencing.
Circadian Control of Systemic Metabolism in Physiology and Type 2 Diabetes
This project aims to uncover how synchronizing energetic stressors with circadian rhythms can improve metabolism and inform new treatments for type 2 diabetes.
Tracking epigenetic plasticity in circulating tumor-derived DNA to monitor drug resistance and guide personalized treatment in cancer patients
EpiGuide aims to develop a blood-based assay to monitor epigenetic mechanisms of drug resistance in cancer, enhancing personalized treatment and early detection of therapy failure.
Opioids and insulin secretion: a new avenue to fight type 2 diabetes
This project aims to explore the role of delta opioid receptors in insulin secretion to develop innovative drug targets for Type 2 diabetes, utilizing advanced genomic and pharmacological methods.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Glucose variability patterns for precision nutrition in diabetesThe GLUCOTYPES project aims to identify early glycaemic patterns and their dietary influences using advanced technologies to develop precision nutrition strategies for Type 2 diabetes prevention and management. | EIC Pathfinder | € 3.988.206 | 2024 | Details |
Beta-cell recovery to counter diabetesDiogenX aims to cure Type 1 Diabetes by regenerating pancreatic beta-cells for autonomous insulin release, with plans to out-license the drug following human clinical proof by 2026. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Mind Game DM2 (MGDM2)Het project richt zich op het verbeteren van de kwaliteit van leven van diabetespatiënten door een integrale leefstijlinterventie en koolhydraatarm dieet, met als doel duurzame mindsetverandering en herstel. | Mkb-innovati... | € 20.000 | 2020 | Details |
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scaleDeveloping a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Linking Intestinal Bacteria and Host Metabolism to Tackle Type 2 Diabetes with Novel FoodDiBaN aims to develop advanced platforms for testing novel insect-based foods to prevent intestinal dysbiosis and Type 2 diabetes, integrating AI for personalized nutritional interventions. | EIC Pathfinder | € 3.999.222 | 2024 | Details |
Glucose variability patterns for precision nutrition in diabetes
The GLUCOTYPES project aims to identify early glycaemic patterns and their dietary influences using advanced technologies to develop precision nutrition strategies for Type 2 diabetes prevention and management.
Beta-cell recovery to counter diabetes
DiogenX aims to cure Type 1 Diabetes by regenerating pancreatic beta-cells for autonomous insulin release, with plans to out-license the drug following human clinical proof by 2026.
Mind Game DM2 (MGDM2)
Het project richt zich op het verbeteren van de kwaliteit van leven van diabetespatiënten door een integrale leefstijlinterventie en koolhydraatarm dieet, met als doel duurzame mindsetverandering en herstel.
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scale
Developing a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support.
Linking Intestinal Bacteria and Host Metabolism to Tackle Type 2 Diabetes with Novel Food
DiBaN aims to develop advanced platforms for testing novel insect-based foods to prevent intestinal dysbiosis and Type 2 diabetes, integrating AI for personalized nutritional interventions.